Impact of juvenile idiopathic arthritis associated uveitis in early adulthood by Haasnoot, A.-M.J.W. (Anne-Mieke J. W.) et al.
RESEARCH ARTICLE
Impact of Juvenile Idiopathic Arthritis
AssociatedUveitis in Early Adulthood
Anne-Mieke J. W. Haasnoot1*, Lenneke A. Vernie1, Aniki Rothova2, Patricia v. d. Doe,
Leonoor I. Los3,4, Nicoline E. Schalij-Delfos5, Joke H. de Boer1
1 Department of Ophthalmology, Utrecht University Medical Center, Utrecht, The Netherlands,
2 Department of Ophthalmology, Erasmus Medical Center, Rotterdam, The Netherlands, 3 Department of
Ophthalmology, Groningen University Medical Center, Groningen, the Netherlands, 4 W.J. Kolff Institute,
Graduate School of Medical Sciences, University of Groningen, Groningen, the Netherlands, 5 Department
of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands
* a.j.w.haasnoot@umcutrecht.nl
Abstract
Background
Typically juvenile idiopathic arthritis (JIA)-associated uveitis (further referred as ‘JIA-uve-
itis’) has its onset in childhood, but some patients suffer its, sometimes visual threatening,
complications or ongoing disease activity in adulthood. The objective of this study was to
analyze uveitis activity, complications and visual prognosis in adulthood.
Methods
In this multicenter study, 67 adult patients (129 affected eyes) with JIA-uveitis were retro-
spectively studied for best corrected visual acuity, visual fields, uveitis activity, topical/sys-
temic treatments, ocular complications, and ocular surgeries during their 18th, 22nd and
30th year of life. Because treatment strategies changed after the year 1990, outcomes were
stratified for onset of uveitis before and after 1990.
Results
Sixty-two of all 67 included patients (93%) had bilateral uveitis. During their 18th life year,
4/52 patients (8%) had complete remission, 28/52 (54%) had uveitis activity and 37/51
patients (73%) were on systemic immunomodulatory treatment. Bilateral visual impairment
or legal blindness occurred in 2/51 patients (4%); unilateral visual impairment or legal blind-
ness occurred in 17/51 patients (33%) aged 18 years. The visual prognosis appeared to be
slightly better for patients with uveitis onset after the year 1990 (for uveitis onset before
1990 (n = 7) four patients (58%) and for uveitis onset after 1990 (n = 44) 13 patients (30%)
were either visual impaired or blind). At least one ocular surgery was performed in 10/24
patients (42%) between their 18th and 22nd year of life.
Conclusions
Bilateral visual outcome in early adulthood in patients with JIA-uveitis appears to be fairly
good, although one third of the patients developed one visually impaired or blind eye.
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However, a fair amount of the patients suffered from ongoing uveitis activity and needed
ongoing treatment as well as surgical interventions. Awareness of these findings is impor-
tant for ophthalmologists and rheumatologists treating patients with JIA-uveitis, as well as
for the patients themselves.
Introduction
Chronic anterior uveitis is the most common extra-articularmanifestation of juvenile idiopathic
arthritis (JIA), a serious disease starting prior to the age of 16 years.[1] During the course of, or
preceding JIA, uveitis occurs in 10% up to 45% of the patients, depending on the specific subtype
of JIA.[1–3] Typically JIA-associated uveitis (further referred as ‘JIA-uveitis’) has its onset in
childhood, but some patients suffer its, sometimes visual threatening, complications or ongoing
disease activity in adulthood. Common complications include band keratopathy, posterior syne-
chiae, cataract, secondary glaucoma and cystoidmacular edema (CME).[4–6]However, previous
clinical studies seldom investigated a follow-up of more than seven years.[7–11] Previously, we
reported on uveitis activity in childhoodand puberty and this study revealed a flare up of uveitis
during puberty.[12] Little is known about JIA-uveitis activity in adulthood, but there are sugges-
tions that uveitis activity may persist in adulthood in 30–63% of the patients. Reported outcomes
differ between various studies due to broad follow-up ranges.[12–18] Therefore, the course of
uveitis activity and outcome in adulthood remain unclear. Furthermore, treatment strategies
changed drastically with the upcoming of methotrexate (MTX) around 1990 and later anti-
TNFα therapy around the year 2000.[19–22] Also, ophthalmologic screening protocols for
patients with JIA were introduced around 1990.[23–25] The objective of this study was to analyze
uveitis activity and its complications and visual prognosis in adults with JIA-uveitis and to com-
pare patients with an onset of uveitis before and after the year 1990.
Methods
A retrospective chart review of 67 patients with JIA-associated chronic anterior uveitis who
had reached the age of 18 years, examined at the tertiary centers University Medical Center of
Utrecht, Rotterdam, Leiden and Groningen during the period of 1974 to 2015, was performed.
The majority of the included patients were of European descent. In 12 patients, follow-up data
at the tertiary centers were not complete, therefore these patients signed an informed consent
form in order to make a copy of the ophthalmologist’s patient’s medical chart from general
hospitals, where these patients had also been treated. These charts were additionally reviewed.
This study was approved by the Institutional ReviewBoard of the Utrecht University Medical
Center and is in compliance with Helsinki principles. The ReviewBoard agreed that patients’
informed consent was not necessary, since the data were analyzed anonymously.
JIA was diagnosed and classified by a pediatric rheumatologist according to the criteria of
the International League of Associations for Rheumatology (ILAR) or by former criteria, such
as the European League Against Rheumatism (EULAR).[26,27] The uveitis diagnosis was
made by an ophthalmologist according to the recommendations of the International Uveitis
study group.[28]
The following demographic and disease characteristics were documented for every patient:
date of birth, gender, JIA subtype, laterality of the uveitis, age at onset of arthritis, age at onset
of uveitis, uveitis onset before 1990 or after 1990, the presence of anti-nuclear antibodies
(ANA) and the presence of Human LeukocyteAntigen B-27 (HLA-B27). Furthermore, the
occurrence of synechiae and band keratopathy and patients’ age at onset of these complications
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were noted, as well as the cataract and glaucoma surgeries being performed, and the age at
which these were done. Finally, the subsequent data were collected at fixed time-points, namely
during the year in which the patients became 18, 22 and 30 years old: activity of uveitis, use of
topical corticosteroids, use of intraocular pressure (IOP) lowering medication, use of systemic
immunomodulatory treatment (IMT), occurrence of complications like CME, papillitis, and
hypotony (defined as an IOP<6mmHg in at least two consecutive visits), best corrected visual
acuity (BCVA) measured with Snellen charts and visual field defects based on examination
with the Rodenstock Peritest or the Humphrey Field Analyzer. When BCVA was measured
more times during a year, the best BCVA of the age year was used for analyses.
Patients diagnosedwith uveitis after the age of 16 years and patients with a JIA subtype
other than juvenile oligoarthritis, extended oligoarthritis or polyarthritis (rheumatoid factor
negative) were excluded. Uveitis was considered active when there were at least 1+ cells in the
anterior chamber, as determined by the grading system of the Standardization of Uveitis
Nomenclature (SUN) working group, at least at one visit during the year of the fixed time-
point.[29] Remission was defined as inactive disease for three months after discontinuing all
treatments for eye disease (SUN). Systemic IMT was noted when used for more than six conse-
cutive months and includedMTX, corticosteroids, adalimumab, infliximab, other diseasemod-
ifying anti-rheumatic drugs (mycophenolate mofetil, azathioprine or cyclosporine), other
biologicals (tocilizumab or etanercept) or other anti-rheumatic drugs (hydroxychloroquine or
sulfasalazine). Starting dose of MTXwas 10–15 mg/m2 body surface once a week, with a maxi-
mum of 20 mg/m2, and starting dose of oral prednisone was generally 1mg/kg body weight. If
compliance with the usage of medication was reported in the patient’s medical chart, these data
were used. Changes in medication, uveitis activity and complications arising within a period of
two months after surgery were not included. Measurements of visual acuity were only included
for analyses if uninfluencedby or corrected for refractive errors (BCVA).
The database was built per patient, with additionally included information per eye for
BCVA, visual field and ocular surgeries. Visual outcome was classified into three groups, based
on the criteria of the SUN working group: visual acuity better than 20/50 was defined as no
visual impairment, visual acuity equal to or less than 20/50 was defined as visual impairment
and visual acuity equal to or less than 20/200 was defined as legal blindness.[29] If patients had
a visual field of 10° or less they were also classified as ‘legal blindness’, according to the criteria
for visual impairment of theWorld Health Organization.[30] Data on visual ability (visual acu-
ity in combination with visual field outcome) per eye were combined to analyze the visual
impairment per patient, primarily using data of the best eye to determine the visual outcome. If
data of the worst eye was used, this is explicitly mentioned.
To study the course of the BCVA, Snellen visual acuity values were transferred to LogMar.
When patients had a visual field of10°, the same LogMar visual acuity as for light perception
was used (LogMar = 2.90). For patients who had no light perception we used a LogMar visual
acuity of 3.20. The reported BCVA’s in this manuscript are reported on a Snellen scale and are
based on per eye analyses.
Statistical analysis was performed using SPSS 21.0 for Windows (IBM Corporation,
Armonk, New York, USA). Normality was tested using the Shapiro-Wilk test. Medians com-
bined with a range were given for not normally distributed variables. A Chi-squared test or
Fisher’s exact test was performed to compare categorical data and a Mann-Whitney U-test was
done to compare medians across groups. To analyze the course of the disease in patients of
whom data was available at 18 and 22 years of age and at 18, 22 and 30 years, the McNemar
test was used to compare dichotomous variables. To compare the visual acuity in these patients,
Snellen BCVA was log transformed and median BCVA’s (with interquartile range (IQR)) were
compared by theWilcoxon signed rank test.
Juvenile Idiopathic Arthritis Associated Uveitis in Adulthood
PLOS ONE | DOI:10.1371/journal.pone.0164312 October 10, 2016 3 / 14
Results
General characteristics of study population
Sixty-seven patients in total were included (129 affected eyes) and 62 (93%) had bilateral uveitis.
Characteristics of the study population at the age of 18, 22 and 30 years (n = 52, 26 and 13 respec-
tively) with uveitis onset before 1990 and after 1990 are shown in Table 1. All data at 30 years
were from patients with uveitis onset before 1990. There were no statistically significant differ-
ences for baseline characteristics after stratifying for uveitis onset before and after the year 1990.
Visual impairment and visual acuity
Data of the visual ability at the different ages are shown in Fig 1. At the age of 18 years, 2/51
patients (4%) were visually impaired or legally blind. One was diagnosed before 1990 and one
after 1990. Seventeen out of 51 patients (33%) had at least one eye which had a visual acuity of
20/50 or worse and/or a visual field of10° of which 13/17 patients were diagnosed after 1990
(which represents 30% of all 44 patients diagnosed after 1990) and 4/17 patients were diag-
nosed before 1990 (which represents 58% of all seven patients diagnosed before 1990).
Of all patients with an impaired visual ability of at least one eye, 10 out of 17 (59%) were
diagnosedwith uveitis before arthritis versus five out of 33 (15%) of the patients with a good
Table 1. Characteristics of patients with juvenile idiopathic arthritis associated uveitis at the age of 18, 22 and 30 years.
< 1990  1990
Characteristics Total 18 years 22 years 30 years 18 years 22 years 30
years
Total no. patients 67 7 8 13 45 18 0
Total no. eyes 129 14 16 26 86 36 NA
Bilateral uveitis no. patients (%) 62 (93) 7 (100) 8 (100) 13 (100) 41 (91) 18 (100) NA
Female, no. patients (%) 50 (75) 6 (86) 7 (88) 12 (92) 30 (67) 13 (72) NA
Median age (y) at onset uveitis
(range)
5.2 (1.2–
14.6)
4.1 (3.0–
9.3)
4.5 (3.0–9.3) 4.9 (3.0–9.3) 5.3 (2.6–
14.6)
5.2 (2.6–
12.7)
NA
Median age (y) at onset arthritis
(range)
3.5 (0.8–
16.1)
3.0 (0.8–
7.4)
2.9 (0.8–7.4) 3.0 (0.8–7.4) 3.8 (0.9–
16.1)
4.7 (1.0–
12.7)
NA
Interval (y) arthritis-uveitis, median
(range)
0.5 (-9.8–
13.3)
0.7 (-3.4–
6.5)
1.6 (-3.4–
6.5)
0.7 (-3.4–
6.5)
0.4 (-9.8–
13.3)
0.5 (-6.7–
6.0)
NA
Median duration (y) of uveitis
(range)
NA 13.9 (8.7–
15.0)
17.5 (12.7–
19.0)
25.1 (20.7–
27.0)
12.7 (3.4–
15.4)
16.9 (9.3–
19.4)
NA
Arthritis onset before uveitis, no.
patients (%)
48 (74) 5 (83) 6 (86) 9 (82) 30 (67) 13 (72) NA
JIA subtype, no. patients (%) Oligoarthritis 35 (52) 4 (57) 4 (50) 5 (38) 28 (62) 9 (50) NA
Extended
oligoarthritis
9 (13) 0 (0) 0 (0) 1 (8) 7 (16) 5 (28) NA
Polyarthritis 15 (22) 1 (14) 1 (13) 2 (16) 8 (18) 4 (22) NA
Unknown 8 (12) 2 (29) 3 (37) 5 (38) 2 (4) 0 (0) NA
ANA, no. patients Total 64 7 8 12 44 18 NA
Positive (%) 52 (81) 6 (86) 7 (88) 11 (92) 37 (84) 15 (83) NA
HLA-B27, no. Patients Total 28 1 2 5 18 8 NA
Positive (%) 5 (18) 0 (0) 0 (0) 1 (20) 3 (17) 0 (0) NA
JIA = juvenile idiopathic arthritis; ANA = antinuclear antibodies; HLA-B27 = human leukocyte antigen B27; NA = not applicable. Per age-group statistical
analyses were performed comparing patients with an uveitis diagnosis before (<) or after () 1990 by the Fisher exact test and Mann-Whitney U test. No
statistically significant differences were found. In the group with an uveitis diagnosis <1990, more data were available at age 30 years than at age 18 or 22
years. Because of the retrospective character of the study, more data were missing at the latter two time-points.
doi:10.1371/journal.pone.0164312.t001
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visual ability (P = .001). Also at the age of 22 years, the two patients (100%) with visual
impairment of the best eye were diagnosedwith uveitis before arthritis, compared to three out
of 22 patients (14%) with normal visual acuity (P = .036).
No differences were found for gender, uveitis onset before 1990 or after 1990, or total num-
ber of ocular surgeries since uveitis onset.
The course of visual acuity could be measured for 23 patients with follow-up data at both 18
and 22 years. The median BCVA between 18 and 22 years (n = 23 patients) appeared to be sta-
ble. Sixteen of these patients (70%) were diagnosed after 1990. Six patients had follow-up data
at all age years (18, 22 and 30 years) and had a median BCVA of one eye of 20/63 (IQR 20/20-
0.25/200) at the age of 18 years and 2/200 (IQR 20/22-0.25/200) at the age of 30 years (P =
.465) and for the other eye a median BCVA of 20/25 at 18 years (IQR 20/16-20/100) and 20/40
at 30 years (IQR 20/25-0.02/200; P = .116). All these six patients were diagnosed before the
year 1990.
Uveitis activity and treatment
Of the 52 patients with available data at the age of 18 years, four patients (8%) were in remis-
sion during the entire year (Fig 2). Almost half of the patients (n = 28/52, 54%) had an episode
Fig 1. Visual impairment of patients with juvenile idiopathic arthritis associated uveitis. Proportion of patients with juvenile idiopathic
arthritis associated uveitis with no visual impairment, visual impairment or legal blindness of the best (left) and worst (right) eye at the age of
18, 22 and 30 years, with uveitis onset before (<) 1990/after () 1990. Visual acuity better than 20/50 was defined as no visual impairment,
visual acuity equal to or less than 20/50 was defined as visual impairment and visual acuity equal to or less than 20/200 was defined as legal
blindness.[29] If patients had a visual field of 10˚ or less they were also classified as ‘legal blindness’, according to the criteria for visual
impairment of the World Health Organization.[30]. Statistical analyses comparing the situation <1990 and1990 were derived from the Fisher
exact test, there were no statistically significant differences. ‘n = ‘ = total number of patients included in the bar.
doi:10.1371/journal.pone.0164312.g001
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of active uveitis during their 18th life year, 37/51 patients (73%) were on systemic IMT and
42/52 (81%) used topical steroids. Four of the 37 (11%) 18 year-old patients on systemic IMT
had no uveitis activity and did not use topical steroids (all diagnosed1990). All others in the
group ‘without remission’ were at least on topical corticosteroids or had uveitis activity.
The majority of 18 year-old patients diagnosed after 1990 were on systemic IMT (n = 36/45,
80%), in contrast to the patients diagnosed before 1990, where only 1/6 patients (17%) was on
systemic IMT during the 18th life year (P = .004). A comparable result was found at the age of
22 years (P = .017, Fig 2). No other statistically significant differences were found for uveitis
activity or treatment between the patients diagnosed before and after 1990.
The different treatment strategies are presented in Fig 3. The figure shows that patients
diagnosed after 1990 were treated with biologicalsmore often than patients diagnosedwith
uveitis before 1990.
Course of complications and surgery
Ten of the 24 patients (42%) with follow-up data available at the age of 18 as well as at the age
of 22 years underwent surgery between their 18th and 22nd year of age. Three/24 patients (14%)
underwent cataract surgery and 9/24 (38%) underwent glaucoma surgery between their 18th
and 22nd birthday.
Seventeen/24 patients (71%) had already had surgery by the time they became 18 years old (6/
24 patients had had surgery for cataract and glaucoma, 10/24 for cataract only, 1/24 for glaucoma
only). Four/24 patients (17%) had their first surgery after the age of 18. Three/24 patients (13%)
never underwent surgery before their 22nd life year. Note that all of these 24 patients had bilateral
uveitis and the majority of patients (n = 17/24, 71%) was diagnosedwith uveitis after 1990.
Fig 4 presents the number of cataract surgeries and type of glaucoma surgeries performed in
the complete study population. Though not statistically significant, these results suggest that
patients underwent glaucoma surgerymore often when having an uveitis onset after 1990.
None of the patients developed posterior synechiae between the age of 18 and 22 years,
though one patient (4%) developed band keratopathy.
Active inflammation in the anterior chamber was less frequent at the 22nd life year (8/23,
35%) compared to the 18th life year (15/23, 65%; P = .039). No differences were found for com-
plete remission of uveitis, presence of CME, use of topical steroids, use of systemic IMT, use of
IOP lowering medication, papillitis or hypotony.
Discussion
Our results document that JIA is not solely a disease of childhood, but that its activity, accom-
panied use of systemic medications, complications and additional visual loss continues in early
adulthood.Only 4% of the JIA-uveitis patients were in remission at 18 years of age.
Previous literature, as presented in Table 2, describedpatients with JIA-uveitis in adulthood,
but broad ranges of follow-up make it difficult to interpret their results. In our study we studied
different outcome measurements at fixed time-points. Further, to get a good impression of the
Fig 2. Uveitis activity, treatment and complications of patients with uveitis associated with juvenile idiopathic arthritis in
adulthood. Outcomes of patients with uveitis onset before (<) and after () the year 1990. At the top: outcomes at age 18; middle:
age 22 years; bottom: age 30 years. Note that all data at age 30 years were from patients with uveitis onset before the year 1990.
Remission was defined as inactive disease for three months after discontinuing all treatments for eye disease.[29] Systemic
immunomodulatory treatment (IMT) was defined ‘Yes’ when used for more than six months. Uveitis activity was defined ‘Yes’
when there were at least 1+ cells in the anterior chamber, as determined by the grading system of the Standardization of Uveitis
Nomenclature (SUN) working group.[29]. CME = cystoid macular edema; IOP = intraocular pressure. *: P < .05; **: P < .005.
‘n = ‘ = total number of patients included in the bar.
doi:10.1371/journal.pone.0164312.g002
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visual ability of the patients, visual acuity cannot be seen apart from visual field outcomes.
Only one previous study of 12 adult JIA-uveitis patients also studied visual field outcomes.[14]
Our study showed a trend towards a slightly better visual outcome for patients diagnosed
after 1990 than for patients diagnosed before 1990. Also, a higher percentage of patients
Fig 3. The use of systemic immunomodulatory treatment in patients with juvenile idiopathic arthritis associated uveitis.
Treatment at the age of 18, 22 and 30 years with uveitis onset before (<) and after () the year 1990. DMARD = disease modifying anti-
rheumatic drugs. A biological was always given combined with a DMARD (in the figure noted as ‘Biologicals’), a DMARD/other drugs
were usually given as combination therapy. ‘n = ‘ = total number of patients included in the bar. The exact treatment, with number of
patients using this treatment in brackets, was: Treatment 18 years, <1990: Corticosteroids (n = 1). Treatment 18 years, 1990:
Corticosteroids (n = 1), Methotrexate (n = 31), Mycophenolate motefil (n = 2), Azathioprine (n = 2), Cyclosporine (n = 1), Adalimumab
(n = 16), Etanercept (n = 1), Infliximab (n = 2). Treatment 22 years, < 1990: Corticosteroids (n = 1), Methotrexate (n = 1).Treatment 22
years, 1990: Corticosteroids (n = 2), Methotrexate (n = 9), Mycophenolate motefil (n = 3), Azathioprine (n = 1), Hydroxychloroquine
(n = 2), Adalimumab (n = 4), Etanercept (n = 2), Tocilizumab (n = 2), Infliximab (n = 1).Treatment 30 years, <1990: Corticosteroids
(n = 4), Methotrexate (n = 5), Mycophenolate motefil (n = 1), Hydroxychloroquine (n = 1), Cyclosporine (n = 1), Sulfasalazine (n = 1),
Tocilizumab (n = 1), Etanercept (n = 1).
doi:10.1371/journal.pone.0164312.g003
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diagnosed after 1990 used systemic IMT, which suggests an improvement of visual outcome
due to novel and more intensive immunomodulating treatment strategies since 1990.[19–22] It
is likely that the use of ophthalmologic screening guidelines for patients with JIA has also con-
tributed to improved visual outcome.[23–25] Furthermore, the awareness of glaucoma
increased during the last decades with earlier and improved interventions and more prevention
of severe glaucomatous visual field loss, as also displayed by Fig 4.[31,32] Also, cataract extrac-
tions are nowadays performed at an earlier stage, preventing development of amblyopia. Previ-
ous literature described a delay of cataract formation in patients treated with MTX, which
means that, since the introduction of MTX as a treatment for JIA-uveitis, children have less
chance to develop cataract at an age vulnerable for developing amblyopia.[33]
Better visual outcome in relation to systemic treatment was also shown by the study of
Gregory et al.[4] Unfortunately, we could not correlate use of systemic IMT to visual outcome,
since our study had data at three time-points rather than continuous data over the years. Addi-
tionally, the prescription of IMTmight have been influencedby uveitis as well as arthritis activ-
ity. Anyhow, only four patients were solely on IMT without uveitis activity or topical steroids
for their uveitis, suggesting that most patients in this study received systemic IMT at least par-
tially for their uveitis.
Though our results suggest that most patients with JIA-uveitis have a fairly good binocular
visual prognosis, with a rather stable visual outcome during the adolescent years, about one
third of the patients with uveitis onset after the year 1990 had at least one visually impaired eye
(Fig 1). In line with previous literature, risk factors for an impaired visual outcome were onset
of uveitis before arthritis and lower age at onset of uveitis.[34] Because of the relatively small
sample size in our patient groups, we cannot exclude that other factors which were described
previously, such as male gender, are also possible risk factors for visual impairment.[6]
Despite the slight improvement of visual acuity and the increased use of systemic IMT after
1990, uveitis in early adulthoodwas active in approximately half of the patients. This is an
Fig 4. Cataract and glaucoma surgery of patients with uveitis associated with juvenile idiopathic arthritis in
adulthood. Proportion of patients who had undergone cataract (left) and glaucoma (right) surgery by the time they were 18,
22 and 30 years old, with uveitis onset before (<) and after () the year 1990. Many patients had multiple glaucoma surgeries;
in this figure patients with at least one glaucoma surgery versus no glaucoma surgeries are presented. Some of the patients
who received a drainage device, also had a trabeculectomy in their medical history and are here included in the ‘Drainage
device’ group. There were no statistically significant differences between the groups with uveitis onset before and after 1990.
‘n = ‘ = total number of patients included in the bar.
doi:10.1371/journal.pone.0164312.g004
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Table 2. Juvenile idiopathic arthritis associated uveitis in adulthood, a literature overview.
Author Nr
patients
Mean/
median age
years
(range)
Follow-up Visual acuity Definition active
uveitis
Uveitis activity Complications, treatment
Packham
et al 2002
[13]
54 35 (19–78)
(= age of
total JIA
group with
246
patients)
Situation at the
end of follow-
up.
NA Not defined NA 66% of the patients had
glaucoma during follow-up,
55% had cataract, 69% had
had eye-surgery (not
specifically during adulthood).
Zak et al
2003[14]
12 32 (22–49) Situation at the
end of follow-
up.
Studied visual field
outcomes.a 1
patient with bilateral
severe visual field
loss. 1 patient with
unilateral VA <0.02.
Not defined NA Almost all patients had
anterior segment findings as
sequelae.
Ozdal et al
2005[15]
18 (30
eyes)
30 (18–48) Situation at the
end of follow-
up. Minimum
follow-up = 2
years.
9 patients (50%)
had a BCVA <20/
150 of at least one
eye.
Presence of cells or
keratic precipitates,
with or without flare.
19 (63%) of the eyes
had active uveitis.
3 eyes with phtisis. 73% (22
eyes) had cataract extraction,
4 eyes (13%) had glaucoma
surgery by drainage device or
trabeculectomy (not
specifically during adulthood).
11 patients (61.1%) required
the use of a systemic
immunosuppresive agent. 16/
18 patients were on topical
steroids.
Kotaniemi
et al 2005
[16]
19 24 (22–26) One consult
for evaluation.
100% binocular
normal BCVA, 3
patients had
unilateral BCVA
<0.1.
Use of topical
corticosteroids and/
or at least 3 cells in
the anterior
chamber.
8 patients had active
uveitis.
4 patients had glaucoma, 5
had cataract. 53% of the
patients were on systemic
IMT. 10/19 patients used
treatment (systemic and/or
topical).
Camuglia
et al 2009
[17]
17 30 (21–43) Situation at the
end of follow-
up.
20% of the eyes
had visual loss up
to 6/12, 13.3% of
the eyes had visual
loss up to 6/60.
Not defined NA 53% of the patients (9
patients, 13 eyes) had new
complications of cataract or
glaucoma after their 16th
birthday. Two eyes had
glaucoma surgery and 10
eyes had cataract surgery
after the age of 16. 30% of the
patients had synechiae during
their uveitis course. 10/17
patients used systemic
treatment, all patients had
topical treatment.
Skarin et al
2009[35]
55 NA Follow-up at
24 years
(range 18–46)
after uveitis
onset.
NA Not defined 49% of the 55
patients had signs of
active uveitis or were
receiving topical
corticosteroids.
12 patients (33%) had
glaucoma, 28 patients (78%)
had cataract.
Oray et al
2016[18]
77 (135
eyes)
29.7 (±11) Situation at the
end of follow-
up.
37 eyes (28%) had
a visual acuity of
20/50. 20 eyes
(15%) had a visual
acuity of20/200.
0.5+ cells in the
anterior chamber.
78 eyes (58%). Ocular surgery in 68 eyes. 13
patients (17%) were treated
with conventional IMT (e.g.
MTX), 52 patients (68%) were
treated with biologicals. At
least one complication in 95
eyes (72%).
This table describes all previous literature on the course of juvenile idiopathic arthritis associated uveitis in adulthood.
aThis was the only study which described visual field outcomes.
NA = not applicable; IMT = immunomodulatory treatment; MTX = Methotrexate.
doi:10.1371/journal.pone.0164312.t002
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important finding to be aware of, since a previous study describeduveitis activity to be associ-
ated with an increased risk of visual loss.[4] It is extremely important for ophthalmologists to
keep a close eye on these patients and treat them accurately, to prevent them frommore bi- or
unilateral visual impairment due to uveitis activity in their future lives. A longer follow-up and
a larger cohort are necessary to be able to document their visual functioning over the years.
Our study cohort presents a representative JIA-uveitis population, as the male-to-female
ratio, median age of arthritis onset and presence of ANA are similar to previous literature.
[12,14–17,35,36]
Because of its retrospective character our study has limitations. There might have been a ter-
tiary referral bias, since patients were selected from a cohort of tertiary centers. Though, this
was minimized as much as possible by retrievingmedical charts from patients being followed
also by their own ophthalmologists outside the tertiary centers. Therefore, the percentage of
patients with active uveitis and/or complications during adulthoodmight be lower than pre-
sented in this study. The sample size of patients evaluated at the age of 30 years is also limited,
and moreover, the data of these patients at their 18th and 22nd year of life were not available,
because it was not possible to retrieve their old medical charts.
Overall results on visual outcomes in this study are quite promising, with an improvement
in visual acuity, probably also due to systemic IMT. Several studies have shown that that the
introduction of MTX and anti-TNFα therapies have been important in the prevention of com-
plications or even the occurrence of uveitis in JIA patients.[4,37] But these treatment strategies
might have significant impact on the quality of life of patients. For example, use of systemic
IMT will result in more visits to the ophthalmologists or rheumatologists, also, these young
adult women might wish to become pregnant which conflicts with the use of most immuno-
suppressive medications. For future research it would be interesting to investigate the effect of
the use of systemic IMT on these aspects, including quality of life of these adult patients.
In conclusion, the results of this study imply that binocular visual outcome in adulthood is
fairly good in most patients with JIA-uveitis and that binocular visual ability seems to be stable
in the first years after puberty. Despite the apparent improvement in visual prognosis in the
last decades, still up to 30% of all adult JIA-uveitis patients have developed severe visual
impairment or even blindness of at least one eye. Also, uveitis activity is continuing in early
adulthood, and the majority of patients need ongoing treatment. Additionally, uveitis associ-
ated complications still arise in early adulthood and a relevant proportion of the patients need
cataract or glaucoma surgery during adulthood. Awareness of these findings is important for
ophthalmologists and rheumatologists treating patients with JIA-uveitis, as well as for the
patients themselves, in order to prevent these patients from becoming visually disabled even
many years after their typical childhoodonset of this disease.
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